UB101 (Bivalent nanobody) is used to treat wet age-related macular degeneration (wet AMD) and works by stopping abnormal blood vessel growth and leakage in the eye(s) that may cause vision loss. The current standard of care for the treatment of wet AMD is administered by intravitreal injection, which brings great inconvenience to patients. Currently, the Group is working on innovative technology to overcome the limitations of intravitreal injection treatment and in preparation for preclinical in vitro and in vivo test.
UB102 (Bispecific nanobody) is capable of blocking two proangiogenic receptors and a combined blockade of them has a greater inhibitory efficacy compared with inhibition of either factor alone. It was designed for the treatment of ocular diseases including wet AMD. Compared to UB101, UB102 can better relieve the symptom and significantly reduce the number of injections, thus reducing the risk of complications caused by eye injections. The Group is developing the bispecific nanobody based on our technology platform as planned.
High technological innovation
DotBodies use large-scale screening and isolation technology, with good affinity, thermal stability and high expression. And the sustained-release technology of nanobodies can prolong the duration of effect.
New drug treatment
Compared with the traditional intravitreal needle injection, the use of needle-free injection of DotBodies can greatly reduce the pain of patients and effectively reduce the risk of complications caused by eye injections.
Stable process and low cost
Mature E. coli expression system, low cost and stable process.
According to CICC International Consulting, along with the milestone progress in the field of antibody engineering and antibody biology, bispecific antibody technology has been continuously innovated and made breakthroughs. It is expected that the global bispecific antibody drug market will grow to 18.4 billion US dollars by 2025.
The global diabetic retinopathy market is expected to grow at a CAGR of 6.4% to reach USD 13.8 billion by 2030. The market size will continue to expand due to increasing patient awareness, rising healthcare spending, and an aging population.
The market size of wet AMD, DME, and other indications is still not large, because there are fewer drugs to choose from. In the future, with the deepening of China's population aging and the launch of domestic manufacturers' drugs, wet AMD and DME are expected to become the fastest growing areas in China's ophthalmic indication market, with a CAGR of more than 40%.
